Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 17

recruiting
3 972
countries
28
conditions
2 103

245 trials match your criteria

Embolism

Not recruiting

Study on REGN7508 for Preventing Blood Clots in Adults After Knee Replacement Surgery

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Enoxaparin Sodium

Adenocarcinoma gastric+1

Not recruiting

Study of Pembrolizumab with Chemotherapy for Patients with Gastric or Gastroesophageal Junction Cancer

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years
  • Substances:Calcium Folinate

Hidradenitis

Not recruiting

Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab

Study on Long-Term Safety and Tolerability of Iptacopan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

InvestigationalNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan

Study on the Effects of Obeticholic Acid and Bezafibrate for Patients with Primary Biliary Cholangitis Who Cannot Tolerate Ursodeoxycholic Acid

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Bezafibrate

Study on Long-term Safety of Seralutinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:LithuaniaLithuania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years
  • Substances:Charcoal, Activated

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:LithuaniaLithuania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab

Study on the Effectiveness and Safety of Gliclazide MR, Dapagliflozin, and Metformin for Patients with Type 2 Diabetes Not Well Controlled with Dapagliflozin

Registered drug
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin

Study on the Effectiveness and Safety of Crovalimab vs. Eculizumab for Adults and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Treated with Complement Inhibitors

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crovalimab

Multiple sclerosis

Not recruiting

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years
  • Substances:Ocrelizumab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.